Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer


Mereo BioPharma Group plc MREO reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with Bristol Myers Squibb Co BMY Opdivo (nivolumab) in select recurrent advanced/metastatic solid tumors.

  • As of the cut-off date, one complete response in cervical cancer, one partial response in ovarian cancer, and four instances of stable disease in ovarian cancer, cervical cancer, and uveal melanoma were observed. 
  • The ovarian cohort has crossed futility for expansion into the second stage of the study (IDMC review pending). 
  • The Company says clinical benefit also occurred in tumor types with historically low response rates to anti-PD-1/PDL-1 antibodies. 
  • The combination of etigilimab and nivolumab has been safe and well-tolerated, with no new safety signals. 
  • The most common treatment-related adverse events were skin reactions, observed in seven patients. None of these reactions required treatment with systemic steroids. 
  • There was one case of immune diabetes mellitus.
  • The ACTIVATE study aims to enroll approximately 125 patients across seven parallel cohorts. 
  • Mereo BioPharma expects to provide additional updates on the study in 2022.
  • Price Action: MREO shares are down 1.93% at $1.78 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralPhase 1 TrialPhase 2 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!